REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B
904.38
USD
1.56
(0.17%)
Pre Open·910.20USD+5.82(+0.64%)
Last updated: · Delayed 15 min
Fair value814.64Plus+11%346Price 904.381,431
Q4 FY2026 · Earnings report
EPS estimate 25.39Revenue estimate 5.85B
OverviewFinancialsForecastEarningsDividendsCompany

Regeneron Pharmaceuticals revenue 1990–2026

Regeneron Pharmaceuticals's revenue in Q3 FY2026, the three months to 30 September 2026, was 5.12B USD, up 36.3% on the same quarter a year before. Regeneron Pharmaceuticals's revenue over the last twelve months was 16.90B USD, up 18.6% on the twelve months before. In fiscal year 2025 it was 14.34B USD, up 1.0% on the year before.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202616.90B+18.59%14.49B4.82B
FY202531 Dec 202514.34B+0.99%12.24B4.50B
FY202431 Dec 202414.20B+8.27%12.23B4.41B
FY202331 Dec 202313.12B+7.76%10.87B3.95B
FY202231 Dec 202212.17B-24.26%10.47B4.34B
FY202131 Dec 202116.07B+89.14%13.35B8.08B
FY202031 Dec 20208.50B+29.58%7.14B3.51B
FY201931 Dec 20196.56B-2.28%5.58B2.12B
FY201831 Dec 20186.71B+14.28%6.13B2.44B
FY201731 Dec 20175.87B+20.82%5.33B1.20B
FY201631 Dec 20164.86B+18.44%4.46B895.52M
FY201531 Dec 20154.10B+45.55%3.64B636.06M
FY201431 Dec 20142.82B+33.96%2.56B348.07M
FY201331 Dec 20132.10B+52.69%1.91B424.36M
FY201231 Dec 20121.38B+209.20%1.26B750.27M
FY201131 Dec 2011445.82M-2.89%410.53M-221.76M
FY201031 Dec 2010459.07M+21.04%437.29M-104.47M
FY200931 Dec 2009379.27M+59.05%363.34M-67.83M
FY200831 Dec 2008238.46M+90.73%226.25M-82.71M
FY200731 Dec 2007125.02M+97.05%0.00-105.60M
FY200631 Dec 200663.45M-4.15%40.71M-102.34M
FY200531 Dec 200566.19M-61.96%41.13M-95.45M
FY200431 Dec 2004174.02M+202.65%22.71M41.70M
FY200331 Dec 200357.50M+161.49%50.82M-107.46M
FY200231 Dec 200221.99M+0.07%15.51M-124.38M
FY200131 Dec 200121.97M-62.93%15.46M-76.18M
FY200031 Dec 200059.28M+71.81%43.71M-23.22M
FY199931 Dec 199934.50M-9.69%30.90M-23.10M
FY199831 Dec 199838.20M+15.41%33.20M-8.60M
FY199731 Dec 199733.10M+37.34%30.50M-11.60M
FY199631 Dec 199624.10M-12.04%23.00M-32.40M
FY199531 Dec 199527.40M+18.10%27.40M-23.50M
FY199431 Dec 199423.20M+118.87%23.20M-30.70M
FY199331 Dec 199310.60M-7.83%10.60M-39.90M
FY199231 Dec 199211.50M+57.53%11.50M-19.10M
FY199131 Dec 19917.30M+46.00%-5.50M-4.50M
FY199031 Dec 19905.00M—-1.30M-3.30M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Regeneron Pharmaceuticals revenue growth by segment

Q3 FY2026 against Q3 FY2025

Collaboration Revenue3.00B
+52.4%
Product1.81B
+13.7%
Product and Service, Other310.00M
+56.4%

Regeneron Pharmaceuticals revenue by segment over time

Collaboration Revenue Product Product and Service, Other IO Agreement Aflibercept Agreement Antibody Collaboration Immuno-oncology Agreement
Fiscal yearCollaboration RevenueProductProduct and Service, OtherIO AgreementAflibercept AgreementAntibody CollaborationImmuno-oncology Agreement
FY20257.33B +21.0%6.31B -17.3%702.60M +36.4%— — — —
FY20246.06B +10.1%7.63B +7.8%515.00M -3.9%— — — —
FY20235.50B +167.3%7.08B +2.7%536.10M +46.8%— — — —
FY20222.06B 6.89B -43.1%365.10M +29.8%— — — —
FY2021— 12.12B +117.6%281.20M — — — —
FY2020— 5.57B +15.2%— — — — —
FY2019— 4.83B +17.7%— — — — —
FY2018— 4.11B — — — — —
FY2017— — — — 24.80M -5.3%553.69M +25.8%323.50M +48.1%
FY2016— — — 640.00M 0.0%26.20M +64.6%440.17M -33.6%218.50M +173.3%

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Regeneron Pharmaceuticals's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.